doi: 10.3389/fneur.2025.1663136 Received 10 July 2025 Accepted 18 August 2025 Published 02 September 2025 Volume 16 - 2025 Edited by Elvio Della Giustina, University Hospital of Modena, Italy Reviewed by Shayne Mason, North-West University, South Africa Valentina Magliocca, Bambino Ges Childrens Hospital, IRCCS, Italy Updates Copyright 2025 Tao, Huo, Hao and Liang
doi: 10.1016/j.etap.2021.103667 29
Because treatment is often ongoing to maintain results, employers must plan for sustained utilization rather than short-term expenses
Our identification of VRK2-mediated SLC7A11 trafficking suggests a potential immune evasion mechanism, as SLC7A11-high tumors often display T cell exclusion phenotypes [37], warranting future investigation into whether VRK2 expression could predict therapeutic response to combined ferroptosis inducers and immune checkpoint inhibitors
PMID: 38085001
Park M, Sharma A, Hj L